Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Global antibiotic consumption rates increased by 46 percent in the last two decades, according to the first study to provide longitudinal estimates for human antibiotic consumption covering 204 countries from 2000 to 2018, published in Lancet Planetary Health by the Global Research on Antimicrobial Resistance (GRAM) Project.

Map showing the global antibiotic consumption per country, showing DDDs (defined daily doses) per 1000 per day.
Global antibiotic consumption, showing DDDs (defined daily doses) per 1000 per day

The excess and inappropriate use of antibiotics is an important driver of drug resistant infections, yet data on antibiotic consumption are scarce. Global Research on Antimicrobial resistance (GRAM), which includes researchers from the University of Oxford, the Mahidol Oxford Tropical Medicine Research Unit (MORU), and the Institute for Health Metric and Evaluation (IHME), used a novel approach that deployed statistical modelling techniques, and incorporated multiple data sources and types, such as large-scale household surveys in low-and middle-income countries, pharmaceutical sales data, and antibiotic consumption data from the World Health Organisation (WHO) and the European Centre for Disease Prevention and Control (ECDC).

The study provides a comparative analysis of total antibiotic consumption rates in humans globally, expressed in the WHO metric of defined daily doses (DDD) per 1000 population per day. This equates to the proportion of people receiving antibiotics on a single day (on each single day in that year) in a given country.

“Understanding the patterns of global antibiotic consumption can help us address a number of public health challenges, from combating drug resistant infections to providing access to basic treatment”  Dr Annie Browne, data scientist, GRAM geospatial modeller, and the study’s first author.

The key findings:

  • High rates of antibiotic consumption were seen in North America, Europe and the Middle East, which were contrasted by very low rates of consumption in sub-Saharan Africa and parts of Southeast Asia.
  • Total antibiotic consumption rates showed a nearly ten-fold variation between countries, ranging from as low as 5·0 DDD to 45·9 DDD per 1000 population per day.
  • Between 2000 and 2018, global antibiotic consumption rates increased by 46% (from 9·8 to 14.3 DDD per 1000 population per day).
  • In high-income countries, consumption rates remained stable between 2000 and 2018
  • In low- and middle-income countries, there was a 76% increase observed between 2000 and 2018 (from 7·4 to 13·1 DDD per 1000 per day).
  • The largest increases in antibiotic consumption rates were seen in the North Africa and Middle East region (111% increase) and South Asia (116%).
  • Large variations in the proportion of antibiotics classes used in different geographic contexts.
  • The highest rates of broad-spectrum penicillin consumption were observed in the High-Income super-region and the lowest in South Asia.
  • In South Asia, consumption rates for fluoroquinolones increased 1.8 fold and for third-generation cephalosporin 37 fold during the study period.

“These findings reveal the huge task ahead, implementing and delivering the WHO Global Action Plan on Antimicrobial Resistance, which relies on optimising antibiotic use and reducing the incidence of infections”, said Professor Christiane Dolecek, the study’s lead author and GRAM scientific lead based in Oxford University’s Centre for Tropical Medicine and Global Health and the Mahidol Oxford Tropical Medicine Research Unit (MORU). “It is imperative to curb the unnecessary demand for antibiotics and combat antimicrobial resistance by improving drinking water and sanitation, vaccine coverage and the availability of rapid diagnostic testing, whilst also increasing access and stewardship of antibiotics when and where they are needed. We hope that this seminal platform and first global country-level benchmarking of antibiotic consumption and usage over a 19-year period up to the pre-COVID-19 era can help inform future interventions to optimise antibiotic use and consumption.”

WHO World Antibiotic Awareness Week (WAAW)

The publication of the study coincides with the WHO World Antibiotic Awareness week, 18-24 November 2021. The 2021 theme, Spread Awareness, Stop Resistancecalls on One Health stakeholders, policymakers, health care providers, and the general public to be Antimicrobial Resistance (AMR) Awareness champions. A link to more information is available here:

This study was funded by the UK Department of Health and Social Care’s Fleming Fund, the Wellcome Trust, and the Bill and Melinda Gates Foundation.

Read the full publication ‘Global antibiotic consumption and usage in humans, 2000-2018: a spatial modelling study’ on the Lancet Planetary Health website

Similar stories

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.

Susie, Phaik Yeong, Richard and Paul among new full Oxford professors!

In the 2021 Oxford Recognition of Distinction round, four MORU colleagues were awarded Full Professor title.